Base-edited T-cells clear incurable leukemia in landmark U.K. trial
Base-edited T-cells have pushed an otherwise incurable blood cancer into remission for the first time in medical history, marking a landmark moment in cancer treatment. Scientists at Great Ormond Street Hospital and University College London developed BE-CAR7, a therapy using donor T-cells precisely engineered through base editing to target T-cell acute lymphoblastic leukemia without attacking healthy tissue. The treatment achieved remission in the majority of trial participants who had already exhausted every conventional option. Unlike standard CAR-T therapies, BE-CAR7 can be batch-manufactured and deployed within days, making cutting-edge immunotherapy faster, potentially cheaper, and more widely accessible.









